BOSTON, May 30, 2024 (GLOBE NEWSWIRE) --Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during th...
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) --Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at ...
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) --Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024, the company granted equity awards to two new employees, pursuant to the company’s 2024 Inducem...
公司地址:201 Brookline Avenue Suite 601 Boston Massachusetts 02215 公司电话:1-617-6030070 今开:8昨收:7.83 最高:8.025最低:7.02 涨停价:跌停价: 总市值:616352755 Verve Therapeutics的热门讨论 持股变动声明 Verve Therapeutics(VERV)01-10 22:05 ...
[2]Scott B Vafai, Verve Therapeutics, Boston, et al. Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - I...
Verve Therapeutics Inc. 201 Brookline Avenue Suite 601 Boston, Massachusetts 02215 Phone1 617 603-0070 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2024 Revenue$11.76M Net Income-$200.07M 2023 Sales Growth505.77% Employees255 ...
Verve Therapeutics, Boston, Massachusetts, United States of AmericaAnne MazzolaVerve Therapeutics, Boston, Massachusetts, United States of AmericaJamie DenizioVerve Therapeutics, Boston, Massachusetts, United States of AmericaTaiji MizoguchiVerve Therapeutics, Boston, Massachusetts, United States of America...
BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the expansion of its relationship with Eli Lilly and Comp...
BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year global research collaboration focused on discovering and developing anin vivogene editing ...
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital Jun. 17, 2022 at 12:26 p.m. ETby Tomi Kilgore Verve Therapeutics reiterated as hold with $58 stock price target at Stifel Dec. 23, 2021 at 6:59 a.m. ETby Ciara Linnane ...